secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0001437749-24-013283
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen announces positive Phase 2A results for PH15 nasal spray improving psychomotor impairment from mental fatigue
--------------------------------------------------------------------------------

- PH15 nasal spray demonstrated statistically significant improvement in reaction time versus placebo and caffeine (p<0.001) in sleep-deprived participants.
- Phase 2A pilot study (2011, acquired via Pherin in February 2023) enrolled 10 participants in a crossover design.
- PH15 was safe and well-tolerated; adverse events comparable to placebo, with brief nasal itching in one subject.
- CEO Shawn Singh highlighted potential for shift work disorder, sleep apnea, and narcolepsy patients.
- No serious adverse events reported; caffeine group experienced palpitations, euphoria, dry mouth, stomachache, and polyuria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924013283/0001437749-24-013283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924013283/vtgn20240425_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-013283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer